FORTEO

This brand name is authorized in Australia, Brazil, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, United States, South Africa

Active ingredients

The drug FORTEO contains one active pharmaceutical ingredient (API):

1 Teriparatide UNII 10T9CSU89I - TERIPARATIDE

Teriparatide (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Teriparatide is a bone formation agent to treat osteoporosis. The skeletal effects of teriparatide depend upon the pattern of systemic exposure. Read about Teriparatide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FORTEO Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H05AA02	Teriparatide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 9411H
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 507612110017403
Country: CA	Health Products and Food Branch	Identifier(s): 02254689
Country: HK	Department of Health Drug Office	Identifier(s): 59594
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4730
Country: JP	医薬品医療機器総合機構	Identifier(s): 2439400G1020
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 10310
Country: SG	Health Sciences Authority	Identifier(s): 12593P
Country: US	FDA, National Drug Code	Identifier(s): 0002-8400
Country: ZA	Health Products Regulatory Authority	Identifier(s): 36/21.4/0334